Biopharma News

Dec 13, 2017
By BioPharm International Editors
In partnership with Indian pharmaceutical firm, Torrent Pharmaceuticals, Novo Nordisk has expanded an insulin manufacturing facility at Torrent’s Indrad, Gujarat, India site.
Dec 13, 2017
By BioPharm International Editors
The approval for Admelog (insulin lispro injection) marks the first short-acting insulin approved as a “follow-on” product.
Dec 12, 2017
By BioPharm International Editors
SGS has introduced a Sanger sequencing service at its Glasgow, United Kingdom, laboratory to support genetic stability testing and perform identity testing on cell banks, plasmids, and viral seeds/vectors.
Dec 12, 2017
By BioPharm International Editors
The agency has approved Nucala (mepolizumab) to treat Eosinophilic Granulomatosis with Polyangiitis (EGPA) to GlaxoSmithKline. This indication is the first FDA-approved therapy specifically to treat EGPA.
Dec 12, 2017
By BioPharm International Editors
The partnership aims to develop and commercialize a skin-care drug candidate being developed to treat actinic keratosis, which, left untreated, can progress to cancer.
Dec 11, 2017
By BioPharm International Editors
FDA has accepted for review Eli Lilly and Company’s biologic drug candidate that is in development for treating migraine.
Dec 08, 2017
By BioPharm International Editors
Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.
Dec 04, 2017
By BioPharm International Editors
The acquisition deepens Astellas’ involvement in the development of a pipeline of therapeutics focused on mitochondrial function.
Dec 04, 2017
By BioPharm International Editors
FDA has approved Mylan’s biosimilar to Roche’s blockbuster anti-cancer biologic, Herceptin.
Dec 01, 2017
By BioPharm International Editors
The company has opened a new California facility that, combined with its existing site in Foster City, CA, will quadruple its laboratory footprint for gene therapy products.
native1_300x100
lorem ipsum